Effect of Kangshuanyihao on no-reflow after PCI in patients with acute ST-segment elevation myocardial infarction

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039399

Enrollment

Unknown

Registered

2020-10-26

Start date

2018-10-23

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Intervention group:aspirin + ticagrelor / clopidogrel + anti-embolization I, served 30 minutes before surgery.

Control group:aspirin + ticagrelor / clopidogrel standard treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The selected patients were all patients with myocardial infarction; 2. All the selected cases were diagnosed as ST-segment elevation myocardial infarction patients; 3. All the selected cases received emergency PCI; 4. Patients with a single vessel requiring stenting. Informed consent of patients and their families.

Exclusion criteria

Exclusion criteria: 1. Suffering from severe liver disease patients; 2. Patients with renal insufficiency; 3. Patients with blood system diseases and coagulopathy; 4. Patients with obvious infection.

Design outcomes

Primary

Measure	Time frame
Slow blood flow / no reflow rate after PCI;	—

Secondary

Measure	Time frame
Evaluation of angina pectoris symptoms;Troponin I;Platelet function;Detection of indicators of inflammation, endothelial function, etc.;Cardiac ultrasound evaluation;	—

Countries

China

Contacts

Public ContactChen Jiandong

Nanjing University of Chinese Medicine

lamala@126.com+86 13813960727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026